2024 Volume 37 Issue 2 Pages 334-338
Objective : To investigate the safety of transurethral lithotripsy (TUL) during anticoagulant treatment.
Subjects and methods : The study included 72 patients who underwent TUL at our hospital between December 2021 and July 2023. The patients were divided into two groups : a group taking oral antithrombotic medication and a control group. Outcome measures included postoperative hematuria, postoperative fever, hospitalization extension, prolonged catheterization, and stone-free rate.
Results : The oral antithrombotic group had 13 patients, and the control group had 59 patients. In the antithrombotic group, 4 patients were administered antiplatelet medication (aspirin), 8 patients were administered anticoagulant medication (2 rivaroxaban, 2 edoxaban, 1 dabigatran, 1 apixaban, and 2 warfarin), and 1 patient was administered both antiplatelet and anticoagulant medication (apixaban and clopidogrel). The median ages of the antithrombotic and control groups were 79 (55-85) and 61 (38-90) years, respectively. Hematuria was found in 38％ and 18％ of the oral antithrombotic and control groups, respectively (P＝0.15), postoperative fever in 7.7％ and 6％ (P＝1.00), prolonged hospital stays in 23.1％ and 6.8％ (P＝0.11), and catheterization in 38.5％ and 17％ (P＝0.13). The stone-free rates were 100％ and 84％, respectively (P＝0.2). In terms of side effects, there was no statistically significant difference between the antiplatelet or antithrombotic and the controls.
Conclusion : The use of antithrombotic drugs did not increase the incidence of side effects, indicating that TUL can be performed safely under antithrombotic medication.
